Clinical value of cancer-associated myositis-specific antibodies, anti-transcriptional intermediary factor 1-γ, and anti-nuclear matrix protein 2 antibodies in a retrospective cohort of dermatomyositis/polymyositis in a Japanese community hospital
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Rheumatology"
DOI: 10.1007/s10067-022-06166-3
Abstract: Among the myositis-specific antibodies (MSA), anti-transcriptional intermediary factor 1 (TIF1)-γ and anti-nuclear matrix protein 2 (NXP2) antibodies are reportedly associated with cancer-associated myositis (CAM). We aimed to investigate patient characteristics of CAM and the clinical… read more here.
Keywords: cancer associated; cancer; myositis; factor ... See more keywords